Marine natural products: A lead for anti-cancer

Indian Journal of Geo-Marine Sciences

Volumn 41, Issue 1, 2012, Pages 27-39

  Sarfaraj, Hussain Md ^a   Sheeba, Fareed ^a   Saba, Ansari ^a   khan, Mohd Sajid ^a  

^a INTEGRAL UNIVERSITY   (India)

Author keywords

Bryostatin1; Didemnin B; Dolastatin; Kahalalide F; Marine natural products

Indexed keywords

ANIMAL PRODUCT; BIOTECHNOLOGY; CANCER; CHEMICAL COMPOSITION; DISEASE TREATMENT; DRUG DEVELOPMENT; MARINE RESOURCE; MEDICINE; ORGANIC NITROGEN COMPOUND; SPONGE;

CRYPTOTHECA;

EID: 84865321509     PISSN: 25826506     EISSN: 25826727     Source Type: Journal    
DOI: None     Document Type: Article

References (124)

1. Jimeno J M. A clinical armamentarium of marine derived anti-cancer compounds, Anticancer Drugs, 13 (2002) (suppl 1): S15-19.Pomponi S A
2. The bioprocess-technological potential of the sea. J Biotechnol., 70 (1999) 5-13
3. Narsinh L, Thakur A, Roopesh Jain, Filipe Natalio, Bojan Hamer, Archana N T, Werner E G, Müller, Marine molecular biology: An emerging field of biological sciences. Biotechnol Adv., 26 (2008) 233-24
4. Waseem Gul, Hamann T M, Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases
5. Cragg G M, Newman D J, Weiss R B, Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin Oncol., 24 (1997) 156-63
6. Pomponi A S. The bioprocess-technological potential of the sea. J Biotechnol 70 (1999) 5-13
7. Schweitzer J, Handley F G, Edwards J, Summary of the workshop on drug development, biologic diversity, and economic growth. J Natl Cancer Inst., 83 (1991) 1294-98
8. Rinehart K L, Antitumor compounds from tunicates. Med Res Rev., 20 (2000) 1-27
9. Molecular biology in marine science. Scientific questions, technological approaches and practical implications. Committee on Molecular Marine Biology, Ocean Studies Board, National Research Council. Washington, D.C. National Academy Press; 1994 (http://www.nap.edu/catalog.php?record_id=9119#toc)
10. Vandana Srivastava, Arvind Singh Negi,. Kumar J K, Gupta M M, Suman P, Khanuja S, Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bio & Med Chem., 13 (2005) 5892-5908
11. Blunt J W, Copp B R, Munro M H G, Northcote P T, Prinsep M R. Marine natural products. Nat Prod Rep., 22 (2005) 15-61
12. Faulkner J. Marine natural products. Nat Prod Rep., 19 (2002) 1-48
13. Newman D J, Cragg G M. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod., 67 (2004) 1216-38
14. Sipkema D, Franssen M C, Osinga R, Tramper J, Wijffels R H. Marine sponges as pharmacy. Mar Biotechnol., 7 (2005) 142-62
15. Mayer A M S, Gustafson K R, Marine Pharmacology in 2003-4: Antitumor and cytotoxic compounds. Eur J Cancer., 43 (2006) 2241-70
16. Mayer A M S, Rodríguez A D, Berlinck R G S, Hamann M T. Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol, Toxicol Pharmacol., 145 (2007) 553-81
17. Rawat D S, Joshi M C, Joshi P, Atheaya H. Marine peptides and related compounds in clinical trial. Anti-Cancer Agents Med Chem., 6 (2006) 1-8
18. Haefner B. Drugs from the deep:marine natural products as drug candidates. Drug Discov Today, 8 (2003) 536-44
19. Donadio S, Monciardini P, Alduina R, Mazza P, Chiocchini C, Cavaletti L, Microbial technologies for the discovery of novel bioactive metabolites. J Biotechnol., 99 (2002) 187-98
20. Rondon M R, August P R, Bettermann A D, Brady S F, Grossman T H, Liles M R, Cloning the soil metagenome: a strategy for accessing the genetic and functional diversity of uncultured microorganisms, Appl Environ Microbiol., 66 (2000) 2541-7
21. Keller M, Zengler K, Tapping into microbial diversity. Nat Rev Microbiol., 2 (2004) 141-50
22. Jimeno J, Faircloth G, Fernández Sousa-Faro J M, Scheuer P and Rinehart K. New Marine Derived Anticancer Therapeutics - A Journey from the Sea to Clinical Trials. Mar. Drugs, 1 (2004) 14-29
23. Craigg G M, Newman D J, Weiss R B, Coral reefs, forests and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin. Oncol, 24 (1997) 156-163
24. Newman D J, Cragg G M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem., 11 (2004) 1693-1713
25. Newman D J, Cragg G M. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod., 67 (2004) 1216-1238
26. Proksch P, Edrada R A and Ebel R. Appl Microbial Biotechnol., 59 (2002)125-134
27. Proksch P, Ebel R., Edrada R A, Wray V and Steube K, In Marine Molecular Biotechnology (ed. Müller, W. E. G.), Springer- Verlag, Berlin, (2003) 117-142
28. Xianghui Ma, Zhiwen Wang. Anticancer drug discovery in the future: an evolutionary prospective. Drug disco today 14 (23/24), (2009) 1137-1144
29. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer, 2 (2002) 143-148
30. Wani M C. Plant antitumor agents V.I. The isolation and structure of taxol, a novel anti-leukemic and antitumor agent from Taxus breoifolia. J Am Chem Soc., 93 (1971) 2325-2327
31. Capon R J. Marine bioprospecting-trawling for treasure and pleasure. Eur J Org Chem., 9 (2001) 633-645
32. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today, 8 (2003) 536-544
33. Haefner, B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov. Today, 8(12) (2003) 536
34. Wall M E. Camptothecin and Taxol: discovery to clinic. Med Res Rev., 18 (1998) 299-314
35. Cirla A and Mann J. Combrestatins: from natural product to drug discovery. Nat Prod Rep., 20 (2003) 558-564
36. Konig G M, Wright A D, Sticher O, Angerhofer C K, Pezzuto J M. Biological activities of selected marine natural products. Planta Med., 60 (1994) 532-37
37. Faulkner D J. Marine natural products. Nat Prod Rep., 18 (2001) 1-49
38. Cvetkovic R S, Figgitt D P, Plosker G L. ET-743. Drugs, 62 (2002) 1185-92
39. Canel C. Podophyllotoxin. Phytochemistry, 54 (2000) 115-120
40. Johnson, I.S. et al. (1963). The Vinca alkaloids: a new class of oncolytic agents. Cancer Res. 23, 1390
41. Anake Kijjoa and Pichan Sawangwong. Drugs and Cosmetics from the Sea. Mar Drugs, 2 (2004) 73-82
42. Adriana B, Rocha D A, Rafael M, Lopes and Gilberto Schwartsmann. Natural products in anticancer therapy. Current Opinion in Pharmacol., 1(2001) 364-369
43. Schwartsmann G. Marine organisms and other novel natural sources of new anticancer drugs. Ann Oncol., 11 (2000) 235-243
44. Schwartsmann G, Rocha A B, Berlinck R, Jimeno J: Marine organisms as a source of new anticancer agents. Lancet Oncol., 2 (2001) 221-225
45. Pomponi A S. The bioprocess-technological potential of the sea. J Biotechnol., 70 (1999) 5-13
46. Schweitzer J, Handley F G, Edwards J, Harris W F, Grever M R, Schepartz S A, Cragg G, Snader K, Bhat A. Summary of the workshop on drug development, biological diversity, and economic growth. J Natl Cancer Inst., 83 (1991) 1294-1298
47. Rinehart K L. Antitumor compounds from tunicates. Med Res Rev., 20 (2000) 1-27
48. Chun H G, Davies B, Hoth D, Suffness M, Plowman J, Flora K, Grieshaber C, Leyland-Jones B: Didemnin B. The first marine compound entering clinical trials as an anti-neoplastic agent. Invest New Drugs, 4 (1986) 279-284
49. Halvorson H O. Aquaculture, Marine Sciences and Oceanography: A Confluence Connection. New Engl J Higher Ed Econ Dev, 13 (1998) 28-42
50. Scheuer P J. Marine Metabolites as Drug Leads-Retrospect and Prospect: In Biochemical Aspects of Marine Pharmacology. Lazarovici P, Spira M E, Zlotkin Eliahu Eds, Alaken Inc.: Fort Collins, Colorado, (1996) 1-12
51. Rinehart K L, Kishore V, Bible K C, Sakai R., Sullins D W, Li K M. Didemnins and Tunichlorin: Novel Natural Products from the Marine Tunicate Trididemnum solidum. J. Nat. Prod., 51 (1988) 1-21
52. Rinehart K, Gloer J, Cook J, Carter J, Mizsak S, Scahill T. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 103 (1987) 1857-9
53. T Luke Simmons, Eric Andrianasolo, Kerry McPhail, Patricia Flatt, and William H, Gerwick. Marine natural products as anticancer drugs. Mol Cancer Ther., 4(2) (2005) 333-42
54. Montgomery D, Zukoshi C F. Transplantation, (1985) 40-49
55. Nuijen B, Bouma M, Manada C. Pharmaceutical development of anticancer agents derived from marine sources. Anticancer Drugs, 11 (2000) 793-811
56. Scheuer P J. Marine Metabolites as Drug Leads-Retrospect and Prospect: In Biochemical Aspects of Marine Pharmacology. Lazarovici P, Spira M E, Zlotkin Eliahu Eds, Alaken, Inc Fort Collins, Colorado, (1996) 1-12
57. Vries D E, Beart D J P M. Fishing for Drugs from the Sea: Status and Strategies. TiP.S., (1995) 16, 275-279
58. Yamada K Okija M, Kigoshi H, Suenaga K. Cytotoxic Substances from Opisthobranch Molluscs: In Drugs From The Sea; Fusetani, N., Ed.; Karger AG: Basel, (2000) 59-73
59. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des., 5 (1999) 139-62
60. Gilberto Schwartsmann, Adriana Brondani da Rocha, Roberto GS, Berlinck and Jose Jimeno. Marine organisms as a source of new anticancer agents. Lancet Oncol., 2 (2001) 221-25
61. Bai R, Pettit G R, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol., 39 (1990) 1941-49
62. Pathak S. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Rep., 5 (1998) 373-76
63. Wright J J, Blatner G, Cheson B D. Clinical trials referral resource, Clinical trials of dolastatin-10. Oncology, 3 (1999) 68-70
64. Madden T, Tran H T, Beck D. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res., 6 (2000) 1293-301
65. Wender P A, Hinkle K W, Koehler M F, Lippa B. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med Res Rev., 19 (1999) 388-407
66. Krug L M, Miller V A, Kalemkerian G P. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol., 11 (2000) 227-28
67. Pettit G R. Isolation and structure of bryostatin-1. J Am Chem Soc., 104 (1982) 6846-48
68. Trenn G. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol., 140 (1988) 433-39
69. Kobayashi M, Natsume T, Tamaoki S. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Re., 88 (1997) 316-27
70. Hornung R L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro and in vivo activity. Cancer Res., 52 (1992) 101-07
71. Varterasian M.L. Phase I study of bryostatin-1 in patients with relapsed non-Hodgkińs lymphoma and chronic lymphocytic leukemia. J Clin Oncol., 16 (1998) 56-62
72. Jayson G C. A phase I trial of bryostatin 1 in patients with advanced malignancies using a hour intravenous infusion. Br J Cancer., 72 (1995) 461-68
73. Prendiville J. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer, 68 (1993) 418-24
74. Propper D J, Macaulay V, Obyrne K J. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer, 78 (1998) 1337-41
75. Gerwick W H, Tan L T, Sitachitta N. Nitrogen-containing metabolites from marine cyanobacteria. In: Cordell G, editor. The alkaloids. San Diego: Academic Press, (2001) 75-184
76. Kan Y, Fujita T, Sakamoto B, A new cyclic depsipeptide from the hawaiian green alga bryopsis species. J Nat Prod., 62 (1999) 1169-72
77. Menon K, Alvarez E, Forler P, Antitumor activity of cryptophycins: Effect of infusion time and combination studies. Cancer Chemother Pharmacol., 46 (2000) 142-49
78. Hamann M T, Otto C S, Scheuer P J. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J Org Chem., 61 (1996) 6594-660
79. Hamann M T, Scheuer P J. Kahalalide F: A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc., 115 (1993) 5825-6
80. Lopez-Macia A, Jimenez J C, Royo M, Giralt E, Albericio F. Synthesis and structure determination of Kahalalide F. J Am Chem Soc., 123 (2001) 11398-401
81. Faircloth G T, Smith B, Grant W, Selective antitumor activity of Kahalalide F, a marine-derived cyclic depsipeptide. Proc Am Assoc Cancer Res., 42 (2001) 1140
82. Cragg G M, Newman D J, Snader K M, et al. Natural products in drug discovery and development. J Nat Prod., 60 (1997) 52-60
83. Schwartsmann G, Workmann P. Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer., 29 (1993) 3-14
84. Schwartsmann G. Marine organisms and other novel natural sources of new cancer drugs. Ann Oncol., 11 (2000) 235-43
85. Cragg G M, Newman D J. Discovery and development of anti-neoplastic agents from natural sources. Cancer Invest., 17 (1999) 153-63
86. Christian M C, Pluda J M, Ho T C, Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute. Semin Oncol., 24 (1997) 219-40
87. Marwa Donia and Mark T Hamann. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis., 3 (2003) 338-48
88. Olivera B M. Conotoxin MVIIA: from marine snail venom to analgesic drug. In: Fusetani N, ed. Drugs from the sea. Basel: Karger, (2000) 74-85
89. Mendola D. Aquacultural production of bryostatin 1 and ecteinascidin 743. In: Fusetani N, ed. Drugs from the sea. Basel: Karger, (2000) 120-33
90. Vacelet J, Donadey C. Electron microscope study of the association between some sponges and bacteria. J Exp Mar Ecol., 30 (1977) 301-14
91. Stefania Nobili, Donatella Lippib, Ewa Witortc, Martino Donninic, Letizia Bausi, Enrico Minia, Sergio Capaccioli. Natural compounds for cancer treatment and prevention. Pharmacol Res., 59 (2009) 365-378
92. Mayer A M, Gustafson K R Marine pharmacology in 2000: anti-tumour and cytotoxicity compounds. Int J cancer, 105 (2003) 291-299
93. Ichiba T, Corgiat J M, Scheuer P J, Kelly-Borges M. 8-hydroxymanzamine A, a beta-carboline alkaloids from a sponge, Pachypellina sp. J Nat Prod., 57 (1994) 168-170
94. Edrada R A, Proksch P, Wray V, Witte L, Muller W E, Van Soest R W. Four new bioactive manzamine-type alkaloids from the Philippine marine sponges Xestopongia ashmorica. J Nat Prod., 59 (1996) 1056-1060
95. Ang K K, Holmes M J, Higa T, Hamann M T, Kara U A (2000). In vitro antimicrobial activity of the beta-carboline alkaloid manzamine A. Antimicrob Agents Chemother., 44 (2000) 1645-1649
96. Ang K K, Holmes M J, Higa T, Kara U A (2001). Immunemediated parasite clearancein mice infected with Plasmodium berghei following treatment with manzamine A. Parasitol Res., 87 (2001) 715-721
97. Yousuf M, Hammond N L, Peng J, Wahyuono S, Mclntosh K A, Charman W N, Mayer A M, Hamann M T. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections and inflammatory diseases. J Med Chem., 47 (2004) 3512-3517
98. Garattini S, La Vecchia C. Perspectives in cancer chemotherapy. Eur J Cancer., 37 (2001) (Suppl 8):S128-47, doi:10.1158/0008-5472.CAN-08-1490
99. Heaney M L, Gardner J R, Karasavvas N, Golde D W, Scheinberg D A, Smith E A, et al. Vitamin C antagonizes the cytotoxic effects of anti-neoplastic drugs. Cancer Res., 68 (2008) 8031-8
100. Frei B, Lawson S. Vitamin C and cancer revisited. Proc Natl Acad Sci USA, 105 (2008) 11037-8, doi:10.1073/pnas.0806433105
101. Faulkner D J, Harper M K, Haygood M G. Symbiotic bacteria in sponges: sources of bioactive substances. In: Fusetani N, editor. Drugs from the sea. Basel, Switz: S. Karger A G, (2000) 107-19
102. Flowers A, Garson M J, Webb R, Dumdei E, Charan R. Cellular origin of chlorinated diketopiperazines in the dictyoceratid sponge Dysidea herbacea (Keller). Cell Tissue Res., 292 (1998) 597-607
103. Unson M D, Faulkner D J. Cyanobacterial symbiont biosynthesis of chlorinated metabolites from Dysidea herbacea (Porifera). Experientia., 49 (1993) 349-53
104. Orjala J O, Gerwick W H. Barbamide, a chlorinated metabolite with molluscicidal activity from the Caribbean cyanobacterium Lyngbya majuscula. J Nat Prod., 59 (1996) 427-30
105. Suarez Y, Gonzalez L, Cuadrado A, Berciano M., Lafarga M., Muñoz A, Kahalalide F, a new marine derived compound induces oncosis in human prostate and breast cancer cells. Mol. Cancer Therapeutics., (2003) 863-872
106. Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun., 342(1) (2006) 101-6
107. Ren X Q, Furukawa T, Yamamoto M, Aoki S, Kobayashi M, Nakagawa M. A functional role of intracellular loops of human multidrug resistance protein 1. J Biochem., (Tokyo) 140(3) (2006) 313-8
108. Guittat L, De C A, Rosu F, Gabelica V, De P E, Delfourne E. Ascididemin and meridine stabilise G-quadruplexes and inhibit telomerase in vitro. Biochim Biophys Acta., 1724(3) (2005) 375-84
109. Hirata K, Muraoka S, Suenaga K, Kuroda T, Kato K, Tanaka H, Structure basis for antitumor effect of aplyronine a. J Mol Biol., 356(4) (2006) 945-54
110. Paleari L, Trombino S, Falugi C, Gallus L, Carlone S, Angelini C, Marine sponge-derived polymeric alkylpyridinium salts as a novel tumor chemotherapeutic targeting the cholinergic system in lung tumors. Int J Oncol 29(6) (2006) 1381-8
111. Taddei M L, Chiarugi P, Cuevas C, Ramponi G, Raugei G. Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug Aplidin. Int J Cancer., 118(8) (2006) 2082-8
112. Powell C T, Yin L. Overexpression of PKCepsilon sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1. Int J Cancer., 118(6) (2006) 1572-6
113. Aoki S, Cho S H, Ono M, Kuwano T, Nakao S, Kuwano M, Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs, 17(3) (2006) 269-78
114. Statsuk A V, Bai R, Baryza J L, Verma V A, Hamel E, Wender P A, Actin is the primary cellular receptor of bistramide A. Nat Chem Biol., 1(7) (2005) 383-8
115. Rizvi S A, Tereshko V, Kossiakoff A A, Kozmin S A. Structure of bistramide A-actin complex at a 135 angstroms resolution. J Am Chem Soc., 128(12) (2006) 3882-3
116. Chiang P C, Chien C L, Pan S L, Chen W P, Teng C M, Shen Y C, Induction of endoplasmic reticulum stress and apoptosis by a marine prostanoid in human hepatocellular carcinoma. J Hepatol., 43(4) (2005) 679-86
117. Muller I M, Dirsch V M, Rudy A, Lopez-Anton N, Pettit G R, Vollmar A M. Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage. Mol Pharmacol., 67(5) (2005) 1684-9
118. Aoki S, Watanabe Y, Sanagawa M, Setiawan A, Kotoku N, Kobayashi M. Cortistatins A, B, C and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. J Am Chem Soc., 128(10) (2006) 3148-9
119. Madiraju C, Edler M C, Hamel E, Raccor B S, Balachandran R, Zhu G, Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry; 44 (45) (2005) 15053-63
120. Xia S, Kenesky C S, Rucker P V, Smith III A B, Orr G A, Horwitz S B. A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin. Biochemistry, 45(39) (2006) 11762-75
121. Minuzzo M, Ceribelli M, Pitarque-Marti M, Borrelli S, Erba E, DiSilvio A, Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol., 68(5) (2005) 1496-503
122. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol., 68(2) (2005) 502-10
123. Lee K H, Nishimura S, Matsunaga S, Fusetani N, Horinouchi S, Yoshida M. Inhibition of protein synthesis and activation of stress-activated protein kinases by onnamide A and theopederin B, antitumor marine natural products. Cancer Sci., 96(6) (2005) 357-64
124. Hamel E, Day B W, Miller J H, Jung M K, Northcote P T, Ghosh A K, Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol., 70(5) (2006) 1555-64